Therefore, we are likely to develop drugs that inhibit the TF USF1 or superenhancers to reduce the expression of FASRL or inhibit the binding of FASRL and ACACA to reduce FA synthesis and ultimately achieve the goal of inhibiting HCC. This evidence concerns the gene NQO1-DT and hepatocellular carcinoma.